We are live on ! Find out more
STAB

Statera Biopharma

Delisted

STAB was delisted on the 11th of January, 2023.

29 hedge funds and large institutions have $4.64M invested in Statera Biopharma in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,447% more capital inflows, than outflows

Capital inflows: $2.6M | Capital outflows: $168K

267% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 3

150% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 4

26% more funds holding

Funds holding: 23 → 29 (+6)

3.82% less ownership

Funds ownership: 7.88% → 4.06% (-3.8%)

97% less call options, than puts

Call options by funds: $1K | Put options by funds: $36K

Holders
29
Holders Change
+6
Holders Change %
+26.09%
% of All Funds
0.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
11
Reduced
3
Closed
4
Calls
$1K
Puts
$36K
Net Calls
-$35K
Net Calls Change
-$51K

STAB Hedge Fund Activity: Q4 2021 in Review

29 of the 6,524 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma (STAB) for Q4 2021, worth a combined $4.64M — up 65% from $2.81M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new STAB positions and 4 closed out — a net gain of 6 holders — while 11 added to existing stakes and 3 trimmed.

The largest buyer was Eaton Vance Management, opening a new position worth an estimated $455K. The largest seller was UBS Group, exiting entirely with an estimated $45K sold.

  • 29 institutional investors held Statera Biopharma (STAB) as of Q4 2021, up from 23 in Q3 2021.
  • Funds reported $4.64M of Statera Biopharma stock for Q4 2021, up 65% quarter-over-quarter.
  • 10 funds opened new Statera Biopharma positions in Q4 2021 and 4 closed out, a net change of +6 holders.
  • The largest Statera Biopharma buyer in Q4 2021 was Eaton Vance Management, an estimated $455K added.
  • The largest Statera Biopharma seller in Q4 2021 was UBS Group, an estimated $45K sold.

Based on aggregated 13F filings for Q4 2021.